AUTHOR=Cai Tong , Yao Yi , Sun Weigui , Lei Peipei 

TITLE=Desmopressin in combination with anticholinergic agents in the treatment of nocturnal enuresis: a systematic review and meta-analysis

JOURNAL=Frontiers in Pediatrics

VOLUME=11

YEAR=2023

URL=https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2023.1242777

DOI=10.3389/fped.2023.1242777

ISSN=2296-2360

ABSTRACT=<sec><title>Background</title><p>The desmopressin combined with anticholinergic agents for the treatment of nocturnal enuresis (NE) remains controversial. This meta-analysis assesses the efficacy and safety of desmopressin compared with desmopressin plus anticholinergic agents for the treatment of NE.</p></sec><sec><title>Methods</title><p>We searched MEDLINE, Embase, and Cochrane Controlled Trials Register databases for RCTs published for the treatment of NE. Systematic review was carried out using the Preferred Reporting Items for Systematic Reviews and Meta-analyses. This meta-analysis used RevMan v.5.1.0 to analyze data.</p></sec><sec><title>Results</title><p>Eight studies involving 600 patients (293 in the combination group and 307 in the desmopressin group) contained meaningful data. The results were as follows: after one month of treatment, compared with the desmopressin monotherapy group, the combination group was significantly better in treating NE in FR (full responders, <italic>P</italic> = 0.003), FR + PR (partial responders) (<italic>P</italic> &lt; 0.0001), and the mean number of wet nights (<italic>P</italic> = 0.004); also, the combination group had a better effect in FR (<italic>P</italic> &lt; 0.00001), FR + PR (<italic>P</italic> = 0.02) and the mean number of wet nights (<italic>P</italic> = 0.04) after 3 months' treatment. For side effects, combination therapy does not cause more adverse events in treating NE (<italic>P</italic> = 0.42).</p></sec><sec><title>Conclusions</title><p>This study elucidates that desmopressin combined with the anticholinergic agent was demonstrated to be more effective in treating NE than desmopressin monotherapy, and the anticholinergic agent does not increase the risk of adverse events (AEs).</p></sec>